M Sennosides
Natural health product licensed in Canada
- Other names
- M Senna, M-Senna 8,6 mg
- Licence holder
- Mantra Pharma Inc.
- NPN or DIN-HM
- 80043280
- Status
- Inactive licence
- Licence date
- 2 July 2013
- Revision date
- 29 June 2017
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Cassia acutifolia Source : Feuille Extract : Matériel brut sec Extraction ratio : 5:1 Dry plant equivalent : 0.043 g Potency : 8.6 mg Hydroxyanthracene derivatives | 0.0086 g | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Cellulose microcristalline, Phosphate dicalcique, Talcum, PEG-150 Pentaerythrityl Tetrastearate, Croscarmellose de sodium, Hydroxypropylméthylcellulose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes et adolescents | minimum: 11 years | minimum: 2 Comprimé ; maximum: 3 Comprimé | 1 day |
Uses authorised in Canada
(Used in Herbal Medicine for the) short-term relief of occasional constipation. (Used in Herbal Medicine to) promote(s) bowel movement (by direct action on the large intestine).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
Do not use if you have abnormal constrictions of the gastrointestinal tract, potential or existing intestinal blockage, atonic bowel, appendicitis, inflammatory colon disease such as Crohn's disease or ulcerative colitis, abdominal pain of unknown origin, undiagnosed rectal bleeding, severe dehydration with depleted water or electrolytes. Do not use if you are pregnant or breastfeeding. Laxatives should not be taken within 2 hours of another medicine because the desired effect of the other medicine may be reduced.
- Effets indésirables connus
Hypersensitivity is known to occur, in which case, discontinue use.
Source
Official Health Canada record, licence 80043280
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2017. Photograph the packaging to check whether it has changed. Photograph the packaging